<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038787</url>
  </required_header>
  <id_info>
    <org_study_id>18097</org_study_id>
    <secondary_id>J2O-JE-EKBB</secondary_id>
    <nct_id>NCT05038787</nct_id>
  </id_info>
  <brief_title>A Study of LY3473329 in Healthy Japanese Participants</brief_title>
  <official_title>A Phase 1, Randomized, Investigator- and Participant-Blind, Placebo-Controlled Study of LY3473329 Multiple-Ascending Dosing in Healthy Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY3473329 in&#xD;
      healthy Japanese participants. The study will also assess how fast LY3473329 gets into the&#xD;
      blood stream and how long it takes the body to remove it. The study is open to healthy&#xD;
      participants. The study will last up to about 71 days, inclusive of screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">January 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 43</time_frame>
    <description>A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3473329</measure>
    <time_frame>Predose on Day 1 through Day 43</time_frame>
    <description>PK: AUC of LY3473329</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3473329</measure>
    <time_frame>Predose on Day 1 through Day 43</time_frame>
    <description>PK: Cmax of LY3473329</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Concentration (Tmax) of LY3473329</measure>
    <time_frame>Predose on Day 1 through Day 43</time_frame>
    <description>PK: Tmax of LY3473329</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3473329</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3473329 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3473329</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3473329</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined through medical history and physical examination.&#xD;
&#xD;
          -  Are males who agree to follow contraception requirements or females not of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  Are 1st generation Japanese defined as the participant, the participant's biological&#xD;
             parents, and all of the participant's biological grandparents must be of exclusive&#xD;
             Japanese descent and born in Japan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history or presence of medical illness.&#xD;
&#xD;
          -  Have significant history of or current psychiatric disorders.&#xD;
&#xD;
          -  Have abnormalities in the 12-lead ECG and blood pressure.&#xD;
&#xD;
          -  Have received treatment with siRNA within the past 12 months or any antisense&#xD;
             oligonucleotide within the past 6 months for lipoprotein(a) [Lp(a)].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-252-0700</phone>
    </contact>
    <investigator>
      <last_name>David Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

